更多栏目
搜索
China NMPA Approved Tracker: Jan 2021
储旻华·2021-02-19
PharmaDJ
Takeda、Beigene、Antengene

China NMPA Approved Tracker: Jan 2021


Writer: Minhua Chu

Editor: Howard Fields


Takeda China launched a new treatment in January that is considered potentially valuable for the company. It is Edarbi (azilsartan medoxomil) an oral angiotensin II receptor blocker (ARB) that was approved by China’s National Medical Products Administration (NMPA) for treating hypertension.


Another notable approval was Beigene (NASDAQ: BGNE, SEHK: 6160.HK) ’s PD-1 monoclonal antibody, tislelizumab, a new indication for first-line treatment of advanced squamous non-small cell lung cancer (NSCLC), in combination with chemotherapy. Just the day before that approval, Novartis got the exclusive global rights (but not Japan) for tislelizumab, for $650 million USD upfront.


微信图片_20210221133403.png


Also, the Chinese biotech Antengene (SEHK: 6996.HK) has acquired exclusive development and commercial rights in several Asia Pacific markets for Xpovio (selinexor), the only oral selective nuclear export inhibitor (SINE) compound of its kind, developed by Karyopharm Therapeutics. Selinexor is also the first NDA for a SINE compound in China.


微信图片_20210221133421.png

文章关键字:China NMPA
1427
谁阅读了此文章?
回复评论0
登录后回复评论,不超过1024个字(当前剩余字数:1024)
储旻华 个人用户

热衷收罗医药圈从研发到上市的各种“八卦”,然后基于事实和数据加以分析

联系方式

联系电话

电子邮箱

chu.minhua@pharmadj.com

公司名称

研发客

公司网站

公司地址

进入主页
Copyright © 2016-2020 研发客.All Rights Reserved.
建议反馈: Support@PharmaDJ.com
备案/许可证编号: 沪ICP备17054709号-1
联系电话:021 - 88194359